Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma.
E. T. Lam
No relevant relationships to disclose
M. K. K. Wong
Consultant or Advisory Role - Prometheus
Honoraria - Speaker's Bureau
N. Agarwal
No relevant relationships to disclose
B. G. Redman
Stock Ownership - Novartis (I)
T. Logan
Consultant or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Novartis; Pfizer; Prometheus; Wyeth
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer; Prometheus; Wyeth
T. W. Flaig
Research Funding - Bayer; GlaxoSmithKline; Novartis; Onyx; Pfizer
J. P. Monk
Consultant or Advisory Role - Bayer; Genentech; Onyx
Research Funding - Prometheus
A. Jarkowski
No relevant relationships to disclose
A. Sendilnathan
No relevant relationships to disclose
M. Bolden
No relevant relationships to disclose
T. Kuzel
Consultant or Advisory Role - Boehringer Ingelheim; Centocor Ortho Biotech; Genentech; Prometheus; Roche
Honoraria - Genentech; Novartis; Pfizer; Prometheus
Research Funding - Bayer; Novartis; Onyx
T. Olencki
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Genentech; GlaxoSmithKline; Pfizer